US Market Product Portfolio for Immunology Drugs 2018 - MedFolio

  • ID: 4418910
  • Report
  • Region: United States
  • 987 pages
  • iData Research
15 % OFF
until Oct 31st 2018
1 of 4

FEATURED COMPANIES

  • AbbVie Inc.
  • AstraZeneca Plc
  • F. Hoffmann-La Roche Ltd
  • Johnson & Johnson
  • Merck KGaA
  • Novartis AG
  • MORE
The full report suite is an extensive market analysis study on the current biologics such as ORENCIA®, HUMIRA®, CIMZIA®, Enbrel®, SIMPONI®, REMICADE®, RITUXAN®, Actemra®, STELARA®, ENTYVIO® and TYSABRI ®. The others segment includes XELJANZ®, promising biologics in pipeline consisting of JAK inhibitors (imposing competition to XELJANZ®) and other TNF and interleukin biologics that will enter the market during the forecast period.
Some of these biologics are approved and used in more than one conditions. Therefore, the market is segmented by diseases. The report comprises market analyses on rheumatoid arthritis, ankylosing spondylitis, Crohn`s disease, ulcerative colitis and psoriasis drugs globally.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie Inc.
  • AstraZeneca Plc
  • F. Hoffmann-La Roche Ltd
  • Johnson & Johnson
  • Merck KGaA
  • Novartis AG
  • MORE
1. EXECUTIVE SUMMARY
MARKET OVERVIEW
COMPETITIVE LANDSCAPE
MARKET TRENDS
KEY MARKET DEVELOPMENTS
MARKETS INCLUDED
VERSION HISTORY

2. 9-STEP METHODOLOGY
Step 1: Project Initiation & Team Selection
Step 2: Prepare Data Systems and Perform Secondary Research
Step 3: Preparation for Interviews & Questionnaire Design
Step 4: Performing Primary Research
Step 5: Research Analysis: Establishing Baseline Estimates
Step 6: Market Forecasts and Analysis
Step 7: Identify Strategic Opportunities
Step 8: Final Review and Market Release
Step 9: Customer Feedback and Market Monitoring

3. MECHANISM OF ACTION
3.1 INTRODUCTION
3.1.1 Tumor Necrosis Factor (TNF)
3.1.2 B-cell Inhibitors
3.1.3 Interleukin Inhibitors
3.1.4 Janus Kinase Inhibitors
3.1.5 Co-stimulation Modulators

4. PRODUCT ASSESSMENT
4.1 KEY MARKETED PRODUCTS
4.1.1 Abatacept (ORENCIA®)
4.1.1.1 Future Developments
4.1.1.2 Currently Marketed Products by Company
4.1.2 Adalimumab (HUMIRA®)
4.1.2.1 Future Developments
4.1.2.2 Currently Marketed Products by Company
4.1.3 Certolizumab pegol (CIMZIA®)
4.1.3.1 Future Developments
4.1.3.2 Currently Marketed Products by Company
4.1.4 Etanercept (ENBREL®, Benepali®)
4.1.4.1 Future Developments
4.1.4.2 Currently Marketed Products by company
4.1.5 Golimumab (SIMPONI®)
4.1.5.1 Future Developments
4.1.5.2 Currently Marketed Products by company
4.1.6 Infliximab (REMICADE®, Inflectra®, Remsima®, Flixabi®, Renflexis®)
4.1.6.1 Future Developments
4.1.6.2 Currently Marketed Products by company
4.1.7 Natalizumab (TYSABRI®)
4.1.7.1 Currently Marketed Products by company
4.1.8 Rituximab (Rituxan®, MabThera®, Rixathon®, Truxima™)
4.1.8.1 Future Developments
4.1.8.2 Currently Marketed Products by company
4.1.9 Tocilizumab (Actemra®/RoActemra®)
4.1.9.1 Currently Marketed Products by company
4.1.10 Tofacitinib (XELJANZ®)
4.1.10.1 Future Developments
4.1.10.2 Currently Marketed Products by company
4.1.11 Ustekinumab (STELARA®)
4.1.11.1 Future Developments
4.1.11.2 Currently Marketed Products by company
4.1.12 Vedolizumab (ENTYVIO®)
4.1.12.1 Currently Marketed Products by company
4.2 KEY PRODUCTS IN PIPELINE
4.2.1 Barcitinb (Olumiant®)
4.2.2 Guselkumab (Tremfya™)
4.2.3 Cobitolimod (Kappaproct®)
4.2.4 Mavrilimumab
4.2.5 Sirukumab
4.2.6 Vobarilizumab
4.3 PRODUCTS IN DEVELOPMENT BY CORE COMPANIES
4.4 CLINICAL TRIAL BY DISEASE
4.4.1 Rheumatoid Arthritis
4.4.1.1 Study Completion Date: 2017
4.4.1.2 Study Completion Date: 2016
4.4.2 Crohn’s Disease (CD)
4.4.2.1 Study Completion Date: 2017
4.4.2.2 Study Completion Date: 2016
4.4.2.3 Study Completion Date: 2015
4.4.3 Ankylosing Spondylitis (AS)
4.4.3.1 Study Completion Date: 2017
4.4.3.2 Study Completion Date: 2016
4.4.3.3 Study Completion Date: 2015
4.4.4 Psoriasis (Ps)
4.4.4.1 Study Completion Date: 2017
4.4.4.2 Study Completion Date: 2016
4.4.5 Ulcerative Colitis (UC)
4.4.5.1 Study Completion Date: 2016
4.4.5.2 Study Completion Date: 2015

5. COUNTRY PROFILE
5.1 UNITED STATES
5.1.1 Population and Demographics
5.1.2 Treatment Size Analysis for 2017
5.1.3 Drug Cost Analysis

6. COMPANY PROFILES
6.1 ABBVIE INC.
6.1.1 Business Overview
6.1.2 Financials
6.1.3 SWOT Analysis
6.1.3.1 Strengths:
6.1.3.2 Weakness:
6.1.3.3 Opportunity:
6.1.3.4 Threats:
6.2 AMGEN INC.
6.2.1 Business Overview
6.2.2 Financials
6.2.3 SWOT Analysis
6.2.3.1 Strengths:
6.2.3.2 Weaknesses:
6.2.3.3 Opportunities:
6.2.3.4 Threats:
6.3 BIOGEN IDEC
6.3.1 Business Overview
6.3.2 Financials
6.3.3 SWOT Analysis
6.3.3.1 Strengths:
6.3.3.2 Weakness:
6.3.3.3 Opportunities:
6.3.3.4 Threats:
6.4 BRISTOL-MYERS SQUIBB
6.4.1 Business Overview
6.4.2 Financials
6.4.3 SWOT Analysis
6.4.3.1 Strengths:
6.4.3.2 Weakness:
6.4.3.3 Opportunities:
6.4.3.4 Threats:
6.5 HOFFMANN-LA ROCHE LTD
6.5.1 Business Overview
6.5.2 Financials
6.5.3 SWOT Analysis
6.5.3.1 Strengths:
6.5.3.2 Weakness:
6.5.3.3 Opportunities:
6.5.3.4 Threats:
6.6 JOHNSON & JOHNSON/JANSSEN
6.6.1 Business Overview
6.6.2 Financials
6.6.3 SWOT Analysis
6.6.3.1 STRENGTHS:
6.6.3.2 Weakness:
6.6.3.3 Opportunities:
6.6.3.4 Threats:
6.7 NOVARTIS AG
6.7.1 Business Overview
6.7.2 Financials
6.7.3 SWOT Analysis
6.7.3.1 STRENGTHS:
6.7.3.2 Weakness:
6.7.3.3 Opportunities:
6.7.3.4 Threats:
6.8 PFIZER INC.
6.8.1 Business Overview
6.8.2 Financials
6.8.3 SWOT Analysis
6.8.3.1 Strengths:
6.8.3.2 Weakness
6.8.3.3 Opportunities
6.8.3.4 Threats:
6.9 TAKEDA PHARMACEUTICAL COMPANY LIMITED
6.9.1 Business Overview
6.9.2 Financials
6.9.3 SWOT Analysis
6.9.3.1 Strengths:
6.9.3.2 Weakness:
6.9.3.3 Opportunities
6.9.3.4 Threats:
6.10 UCB S.A.
6.10.1 Business Overview
6.10.2 Financials
6.10.3 SWOT Analysis
6.10.3.1 Strengths:
6.10.3.2 Weakness:
6.10.3.3 Opportunities:
6.10.3.4 Threats:

ABBREVIATIONS

APPENDIX: COMPANY PRESS RELEASES

List of Charts:
Chart 2 1: Immunology Market by Segment, U.S., 2013 – 2023
Chart 2 2: Immunology Market Overview, U.S., 2016 & 2023
Chart 6 1: Enbrel® Revenue, 2012-2016

List of Figures:
Figure 2 1: Immunology Market Share Ranking by Segment, U.S., 2017
Figure 2 2: Companies Researched in this Report, U.S., 2017
Figure 2 3: Factors Impacting the Immunology Market
Figure 2 4: Recent Events in the Immunology Market, Global, 2016 – 2017, AbbVie
Figure 2 5: Recent Events in the Immunology Market, Global, 2016 – 2017, Amgen
Figure 2 6: Recent Events in the Immunology Market, Global, 2016 – 2017, AstraZeneca
Figure 2 7: Recent Events in the Immunology Market, Global, 2016 – 2017, Biogen
Figure 2 8: Recent Events in the Immunology Market, Global, 2016 – 2017, BMS
Figure 2 9: Recent Events in the Immunology Market, Global, 2016 – 2017, Eli Lilly
Figure 2 10: Recent Events in the Immunology Market, Global, 2016 – 2017, Roche
Figure 2 11: Recent Events in the Immunology Market, Global, 2016 – 2017, Janssen
Figure 2 12: Recent Events in the Immunology Market, Global, 2016 – 2017, Merck
Figure 2 13: Recent Events in the Immunology Market, Global, 2016 – 2017, Merck
Figure 2 14: Recent Events in the Immunology Market, Global, 2016 – 2017, Pfizer
Figure 2 15: Recent Events in the Immunology Market, Global, 2016 – 2017, Takeda
Figure 2 16: Recent Events in the Immunology Market, Global, 2016 – 2017, UCB
Figure 2 17: Immunology Markets Covered, U.S., 2016 (1 of 2)
Figure 2 18: Immunology Markets Covered, U.S., 2016 (2 of 2)
Figure 2 19: Version History
Figure 3 1: Classification by Mechanism of Action
Figure 4 1: Marketed Product Portfolio by Company
Figure 4 2: Marketed Product Portfolio by Company
Figure 4 3: Marketed Product Portfolio by Company
Figure 4 4: Marketed Product Portfolio by Company
Figure 4 5: Marketed Product Portfolio by Company
Figure 4 6: Marketed Product Portfolio by Company
Figure 4 7: Marketed Product Portfolio by Company
Figure 4 8: Marketed Product Portfolio by Company
Figure 4 9: Marketed Product Portfolio by Company
Figure 4 10: Marketed Product Portfolio by Company
Figure 4 11: Marketed Product Portfolio by Company
Figure 4 12: Marketed Product Portfolio by Company
Figure 4 13: Other products in pipeline
Figure 4 14: Pipeline Product Portfolio by Company (1 of 5)
Figure 4 15: Pipeline Product Portfolio by Company (2 of 5)
Figure 4 16: Pipeline Product Portfolio by Company (3 of 5)
Figure 4 17: Pipeline Product Portfolio by Company (4 of 5)
Figure 4 18: Pipeline Product Portfolio by Company (5 of 5)
Figure 4 19: Comparative Efficacy and Safety Study of GP2015 and Enbrel® in Patients With Rheumatoid Arthritis (EQUIRA)
Figure 4 20: Musculoskeletal Ultrasound in Predicting Early Dose Titration With Tocilizumab (RASTS)
Figure 4 21: Prospective Study on Intensive Early Rheumatoid Arthritis Treatment (CURE)
Figure 4 22: A Study To Evaluate The Safety And Efficacy Of Tofacitinib Modified Release Tablets Compared To Tofacitinib Immediate Release Tablets In Adult Patients With Rheumatoid Arthritis
Figure 4 23: Usability of an AI for M923 in Subjects With Moderate to Severe RA
Figure 4 24: Comparison of Combination Disease Modifying Antirheumatic Drugs With Methotrexate Therapy in Early Rheumatoid Arthritis
Figure 4 25: Study to Demonstrate Non-Inferiority Efficacy and Safety of CinnoRA® Produced by CinnaGen Company Versus HUMIRA® for Treatment of Active Rheumatoid Arthritis
Figure 4 26: PK Similarity Prospective Phase 3 Study in Patients With Rheumatoid Arthritis (rituximab)
Figure 4 27: Abatacept Post-marketing Clinical Study in Japan
Figure 4 28: An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate (ORAL STRATEGY)
Figure 4 29: A Study of CNTO 136 (Sirukumab), Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Disease-Modifying Antirheumatic Drug (DMARD) Therapy (SIRROUND-D)
Figure 4 30: An Open-label Extension Study of Certolizumab Pegol in Chinese Patients With Rheumatoid Arthritis Who Enrolled in RA0044 (RAPID-C OLE)
Figure 4 31: A Study Assessing the Safety and Efficacy of Sarilumab Added to Non-MTX DMARDs or as Monotherapy in Japanese Patients With Active Rheumatoid Arthritis (SARIL-RA-HARUKA)
Figure 4 32: Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Figure 4 33: BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Figure 4 34: Efficacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid Arthritis
Figure 4 35: A Study Assessing the Safety and Efficacy of Subcutaneous Actemra®/RoActemra® Alone or in Combination With Non-biologic Antirheumatics in Rhuematoid Arthritis Patients in Latin America With Inadequate Response to Non-biologic Antirheumatic Drugs.
Figure 4 36: A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous Tocilizumab With Methotrexate in Participants With Moderate to Severe Active Rheumatoid Arthritis
Figure 4 37: GP2013 Treatment in Patients With Active Rheumatoid Arthritis, Previously Treated With Rituxan® or MabThera® (ASSIST-RT)
Figure 4 38: A Study Assessing the Efficacy and Safety of Sarilumab Added to MTX in Japanese Patients With Moderately to Severely Active Rheumatoid Arthritis (SARIL-RA-KAKEHASI)
Figure 4 39: A Study of Subcutaneous Actemra®/RoActemra® (Tocilizumab) in Patients With Active Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs
Figure 4 40: Tocilizumab Real-Life Human Factors (RLHFs) Validation Study
Figure 4 41: A Study Comparing Sirukumab (CNTO 136) Monotherapy With Adalimumab (HUMIRA®) Monotherapy in the Treatment of Active Rheumatoid Arthritis (SIRROUND-H)
Figure 4 42: A Study of Actemra®/RoActemra® (Tocilizumab) in Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biologic DMARD Therapy or the First Anti-TNF Biologic Agent
Figure 4 43: A Study to Evaluate Efficacy of Tocilizumab Administered as Monotherapy or in Combination With Methotrexate and/or Other Disease Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis (RA) Participants
Figure 4 44: A Study to Compare FKB327 Efficacy and Safety With HUMIRA® in Rheumatoid Arthritis Patients (ARABESC)
Figure 4 45: A Long-term Safety Extension Study of Tocilizumab in Brazilian Participants With Rheumatoid Arthritis (RA) Who Completed the Studies ML21530 and MA21488 (RITACT)
Figure 4 46: Study to Assess the Immunogenicity, Safety, and Efficacy of High Capacity Process Etanercept in Rheumatoid Arthritis Subjects
Figure 4 47: A Study of Certolizumab Pegol as Additional Therapy in Chinese Patients With Active Rheumatoid Arthritis (RAPID-C)
Figure 4 48: A Study on Safety and Efficacy of Tocilizumab (RoActemra® /Actemra ®) Alone or in Combination With Non-Biologic Antirheumatics in Participants With Rheumatoid Arthritis (OSCAR)
Figure 4 49: Comparison of CHS-0214 to Enbrel® (Etanercept) in Patients With Rheumatoid Arthritis (RA) (CHS-0214-02)
Figure 4 50: A Long Term Extension Study of WA19926 (NCT01649804) of Tocilizumab (RoActemra® /Actemra®) in Participants With Early Moderate to Severe Rheumatoid Arthritis
Figure 4 51: Long-term Safety and Efficacy of ABP 501 in Subjects With Moderate to Severe Rheumatoid Arthritis
Figure 4 52: A Study of Tocilizumab in Comparison to Etanercept in Participants With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors
Figure 4 53: To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis (SARIL-RA-EASY)
Figure 4 54: A Phase 3 Study of NI-071 in Patients With Rheumatoid Arthritis
Figure 4 55: A Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy (SIRROUND-T)
Figure 4 56: Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate
Figure 4 57: Efficacy and Long Term Safety of Adalimumab in Pediatric Subjects Who Have Demonstrated Clinical Response in M06-806
Figure 4 58: Demonstrate Noninferiority in Efficacy and to Assess Safety of CT-P13 in Patients With Active Crohn's Disease
Figure 4 59: Rapidity of Response to Adalimumab Treatment in Patients With Crohn´s Disease (RAPIDA)
Figure 4 60: Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease (CALM)
Figure 4 61: Safety of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease (IBD)
Figure 4 62: Adalimumab-psoriasis and Small Bowel Lesions
Figure 4 63: Endoscopic Ultrasound (EUS) Guided Treatment With Humira for Crohn's Perianal Fistulas
Figure 4 64: A Study of Adalimumab After Dose Escalation in Japanese Subjects With Crohn's Disease
Figure 4 65: Study Investigating Tailored Treatment With Infliximab for Active Crohn's Disease (TAILORIX)
Figure 4 66: Clinical Study of TA-650 in Pediatric Patients With Crohn's Disease
Figure 4 67: Adalimumab on Preventing Post-chirurgic Recurrence on Crohn´s Disease (APPRECIA)
Figure 4 68: Study Comparing the Efficacy and Safety of Continuing Versus Withdrawing Adalimumab Therapy in Maintaining Remission in Subjects With Non-Radiographic Axial Spondyloarthritis
Figure 4 69: A Study of Golimumab in Participants With Active Ankylosing Spondylitis
Figure 4 70: A Study of the Efficacy and Safety of Adalimumab in Pediatric Subjects With Enthesitis Related Arthritis
Figure 4 71: Effect of the Combination of Methotrexate and Adalimumab on Reduction of Immunization in Ankylosing Spondylitis (COMARIS) (COMARIS)
Figure 4 72: The Incidence of Extra-Articular Manifestations in Participants With Ankylosing Spondylitis Treated With Golimumab (MK-8259-012) (GO-EASY)
Figure 4 73: Effect of Golimumab in Participants With Active Axial Spondyloarthritis (P07642, MK-8259-006) (GO-AHEAD)
Figure 4 74: Study to Investigate Efficacy and Safety of Adalimumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP)
Figure 4 75: Phase 3 Study of M923 and HUMIRA® in Subjects With Chronic Plaque-type Psoriasis
Figure 4 76: A Study of Golimumab in Participants With Active Psoriatic Arthritis
Figure 4 77: MYL-1401A Efficacy and Safety Comparability Study to HUMIRA®
Figure 4 78: Concomitant Longitudinal Evaluation of Adalimumab With Methotrexate in the Real World: the CLEAR Study (CLEAR)
Figure 4 79: Comparison of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis (PsOsim)
Figure 4 80: Study to Evaluate Psoriasis Severity and Its Psychosocial Impact Using the Simplified Psoriasis Index (SPI), as Well as Long-term Safety, Tolerability and Efficacy of Secukinumab Administered Subcutaneously in Patients With Moderate to Severe Psoriasis (IPSI-PSO)
Figure 4 81: Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis (TRANSFIGURE)
Figure 4 82: Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis (GESTURE)
Figure 4 83: First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks (FEATURE)
Figure 4 84: Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE) (JUNCTURE)
Figure 4 85: Secukinumab Dosage Optimisation in Partial Responders With Moderate to Severe Plaque-type Psoriasis (GAIN)
Figure 4 86: Vascular Inflammation in Psoriasis - Extension Study (VIP-E)
Figure 4 87: A Study of the Early Activity of Ixekizumab (LY2439821) in Moderate-to-Severe Psoriasis
Figure 4 88: Secukinumab Study in PSOriasis Exploring pruRITUS Intensity and Lesional Biomarkers (PSORITUS)
Figure 4 89: Secukinumab in TNF-IR Psoriasis Patients. (SIGNATURE)
Figure 4 90: Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis
Figure 4 91: Study of Secukinumab Compared to Fumaderm® in Adults With Moderate to Severe Psoriasis. (PRIME)
Figure 4 92: Open-label Study of Subcutaneous Secukinumab to Evaluate Efficacy and Safety in Patients With Plaque Psoriasis Who Had Inadequate Response to Cyclosporine A
Figure 4 93: Comparison of CHS-0214 to Enbrel® (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
Figure 4 94: A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab (NAVIGATE)
Figure 4 95: A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis
Figure 4 96: Evaluation of Cardiovascular Risk Markers in Psoriasis Patients Treated With Secukinumab (CARIMA)
Figure 4 97: Adalimumab-psoriasis and Small Bowel Lesions
Figure 4 98: Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors (OPAL BEYOND)
Figure 4 99: Study to Assess the Efficacy, Safety and Tolerability of Secukinumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP)
Figure 4 100: Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Adalimumab (GP2017) and HUMIRA® (ADACCESS)
Figure 4 101: Trial on the Effect of Adalimumab on Vascular Inflammation in Patients With Psoriasis
Figure 4 102: Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
Figure 4 103: European Safety Registry in Ulcerative Colitis (Study P04808AM3)
Figure 4 104: A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis ((OCT)AVE)
Figure 4 105: Golimumab Utilization and Impact on Ulcerative Colitis (MK-8259-032) (GO-COLITIS)
Figure 4 106: Safety of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease (IBD)
Figure 4 107: A Safety and Effectiveness Study of Golimumab in Japanese Patients With Moderately to Severely Active Ulcerative Colitis
Figure 4 108: Adalimumab in the Treatment of Chronic Pouchitis (ADAP)
Figure 4 109: Preference for a Prefilled Syringe or Smartject™ Device for Delivering Golimumab in Participants Suffering From Moderate-to-severe Ulcerative Colitis (MK-8259-027) (SMART)
Figure 4 110: A Long Term Safety Study of Infliximab (REMICADE®) in in Ulcerative Colitis Patients
Figure 4 111: A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis ((OCT)AVE)
Figure 4 112: A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis ((OCT)AVE)
Figure 4 113: A Study to Evaluate the Impact of Adalimumab on Quality of Life, Health Care Utilization and Costs of Ulcerative Colitis Subjects in the Usual Clinical Practice Setting (InspirAda)
Figure 4 114: An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis
Figure 5 1: Prevalence of the autoimmune diseases in the U.S., 2017
Figure 5 2: Treatment Population Size of Rheumatoid Arthritis, U.S., 2017
Figure 5 3: Treatment Population Size of Crohn’s Disease, U.S., 2017
Figure 5 4: Treatment Population Size of Ankylosing Spondilytis, U.S., 2017
Figure 5 5: Treatment Population Size of Psoriasis, U.S., 2017
Figure 5 6: Treatment Population Size of Ulcerative Colitis, U.S., 2017
Figure 5 7: List of U.S. Retail Pharmacies
Figure 5 8: Drug Prices - Retail Vs Veteran, 2017, U.S. (1 of 2)
Figure 5 9: Drug Prices - Retail Vs Veteran, 2017, U.S. (2 of 2)
Chart 5 10: Drug Prices - Retail Vs Veteran, 2017, U.S.
Figure 6 1: Key Facts, AbbVie Inc., 2017
Figure 6 2: Financials, AbbVie Inc., 2017
Figure 6 3: SWOT Analysis, AbbVie Inc., 2017
Figure 6 4: Key Facts, Amgen, 2017
Figure 6 5: Financial Overview, Amgen, 2017
Figure 6 6: SWOT Analysis, Amgen, 2017
Figure 6 7: Patent Expiries, Enbrel®
Figure 6 8: Key Facts, Biogen Idec
Figure 6 9: Financials, Biogen Idec, 2017
Figure 6 10: SWOT Analysis, Biogen Idec
Figure 6 11: Key Facts, Bristol-Myers Squibb
Figure 6 12: Financials, Bristol-Myers Squibb, 2017
Figure 6 13: Bristol-Myers Squibb, Key Products Revenue (US$M)
Figure 6 14: SWOT Analysis, Bristol-Myers Squibb
Figure 6 15: Key Facts, Hoffman-La Roche Ltd
Figure 6 16: Financials, Hoffman-La Roche Ltd , 2017
Figure 6 17: SWOT Analysis, Hoffman-La Roche Ltd
Figure 6 18: Key Facts, Johnson & Johnson
Figure 6 19: Financials, Johnson & Johnson, 2017
Figure 6 20: SWOT Analysis, Johnson & Johnson
Figure 6 21: Key Facts, Novartis AG
Figure 6 22: Financials, Novartis AG, 2017
Figure 6 23: SWOT Analysis, Novartis AG
Figure 6 24: Key Facts, Pfizer Inc.
Figure 6 25: Financials, Pfizer Inc., 2017
Figure 6 26: SWOT Analysis, Pfizer Inc.
Figure 6 27: Key Facts, Takeda Pharmaceutical Company Limited
Figure 6 28: Financials, Takeda Pharmaceutical Company Limited , 2017
Figure 6 29: SWOT Analysis, Takeda Pharmaceutical Company Limited
Figure 6 30: Key Facts, UCB S.A.
Figure 6 31: Financials, UCB S.A., 2017
Figure 6 32: SWOT Analysis, UCB S.A.
Figure 8 1: Press Release Summary
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • AbbVie Inc.
  • AstraZeneca Plc
  • F. Hoffmann-La Roche Ltd
  • Johnson & Johnson
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Takeda Pharmaceuticals
  • UCB S.A.
Please Note: Not all companies are currently active in every segment or sub-report from this suite.
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll